EP1601357A4 - Inhibiteurs de kinase heterocycliques : procedes d'utilisation et de synthese - Google Patents

Inhibiteurs de kinase heterocycliques : procedes d'utilisation et de synthese

Info

Publication number
EP1601357A4
EP1601357A4 EP04719237A EP04719237A EP1601357A4 EP 1601357 A4 EP1601357 A4 EP 1601357A4 EP 04719237 A EP04719237 A EP 04719237A EP 04719237 A EP04719237 A EP 04719237A EP 1601357 A4 EP1601357 A4 EP 1601357A4
Authority
EP
European Patent Office
Prior art keywords
synthesis
methods
kinase inhibitors
heterocyclic kinase
heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04719237A
Other languages
German (de)
English (en)
Other versions
EP1601357A1 (fr
Inventor
M Arshad Siddiqui
David Belanger
Chaoyang Dai
Lianyun Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of EP1601357A1 publication Critical patent/EP1601357A1/fr
Publication of EP1601357A4 publication Critical patent/EP1601357A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
EP04719237A 2003-03-10 2004-03-10 Inhibiteurs de kinase heterocycliques : procedes d'utilisation et de synthese Withdrawn EP1601357A4 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US45345703P 2003-03-10 2003-03-10
US453457P 2003-03-10
US46091003P 2003-04-07 2003-04-07
US460910P 2003-04-07
US46302503P 2003-04-15 2003-04-15
US463025P 2003-04-15
US50271003P 2003-09-12 2003-09-12
US502710P 2003-09-12
PCT/US2004/007286 WO2004080463A1 (fr) 2003-03-10 2004-03-10 Inhibiteurs de kinase heterocycliques : procedes d'utilisation et de synthese

Publications (2)

Publication Number Publication Date
EP1601357A1 EP1601357A1 (fr) 2005-12-07
EP1601357A4 true EP1601357A4 (fr) 2007-10-03

Family

ID=32996376

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04719237A Withdrawn EP1601357A4 (fr) 2003-03-10 2004-03-10 Inhibiteurs de kinase heterocycliques : procedes d'utilisation et de synthese

Country Status (5)

Country Link
EP (1) EP1601357A4 (fr)
JP (1) JP2006519846A (fr)
CA (1) CA2518398A1 (fr)
MX (1) MXPA05009722A (fr)
WO (1) WO2004080463A1 (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
MX2008002363A (es) 2005-08-17 2008-03-18 Schering Corp Ligandos novedosos de cinasa basados en quinolina de alta afinidad.
EP2043655A2 (fr) 2006-04-25 2009-04-08 Astex Therapeutics Limited Derives de purine et de deazapurine comme composes pharmaceutiques
US7511063B2 (en) * 2006-08-16 2009-03-31 Schering Corporation High affinity quinoline-based kinase ligands
ATE509925T1 (de) 2006-11-17 2011-06-15 Pfizer Substituierte bicyclocarbonsäureamidverbindungen
CA2669590A1 (fr) 2006-12-07 2008-06-12 F. Hoffmann-La Roche Ag 2-aminoquinolines comme antagonistes des recepteurs 5ht(5a)
JP5671236B2 (ja) 2007-03-14 2015-02-18 ランバクシー ラボラトリーズ リミテッド ホスホジエステラーゼ阻害剤としてのピラゾロ（３，４−ｂ）ピリジン誘導体
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
EP2150115B1 (fr) * 2007-05-23 2013-09-18 Merck Sharp & Dohme Corp. Antagonistes du récepteur de la cyclopropylpyrrolidine orexine
US8614326B2 (en) 2007-08-22 2013-12-24 Allergan, Inc. Therapeutic quinoline and naphthalene derivatives
JP2010540483A (ja) * 2007-09-27 2010-12-24 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ５ａ受容体アンタゴニストとしてのキノリン誘導体
RS53552B1 (en) 2007-10-11 2015-02-27 Astrazeneca Ab DERIVATI PIROLO [2,3-D] PIRIMIDINA KAO INHIBITORI PROTEIN KINAZE B
JP5441705B2 (ja) 2007-10-15 2014-03-12 武田薬品工業株式会社 アミド化合物およびその用途
AU2008331733A1 (en) 2007-11-02 2009-06-11 Vertex Pharmaceuticals Incorporated [1H- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase C-theta
WO2009095752A1 (fr) * 2008-01-29 2009-08-06 Glenmark Pharmaceuticals, S.A. Dérivés de pyrazole condensés en tant que modulateurs du récepteur cannabinoïde
MX2010009574A (es) * 2008-03-05 2010-09-24 Hoffmann La Roche 2-aminoquinolinas.
CA2711247A1 (fr) * 2008-03-07 2009-09-11 F. Hoffmann-La Roche Ag 2-aminoquinoleines
MX2010009403A (es) 2008-03-07 2010-09-24 Hoffmann La Roche Derivados de 2-aminoquinolina.
JP2011513452A (ja) * 2008-03-12 2011-04-28 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ５ａ受容体アンタゴニストとしての２−アミノキノリン
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
ES2456275T3 (es) 2009-02-27 2014-04-21 Ambit Biosciences Corporation Derivados de quinazolina moduladores de la quinasa JAK y su uso en métodos
CA2754058A1 (fr) * 2009-03-02 2010-09-10 Sirtris Pharmaceuticals, Inc. Quinoleines substituees en 8 et analogues associes utilises comme modulateurs de sirtuine
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
BR122019013687B1 (pt) * 2009-06-12 2020-04-14 Abivax composto de fórmula (i)
MA33920B1 (fr) * 2009-12-17 2013-01-02 Merck Sharp & Dohme Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
CA2786245A1 (fr) 2010-01-29 2011-08-04 Boehringer Ingelheim International Gmbh Naphtyridines substituees et leur utilisation comme inhibiteurs de syk kinase
WO2011159554A1 (fr) * 2010-06-15 2011-12-22 Merck Sharp & Dohme Corp. Modulateurs allostériques positifs du récepteur m1 de l'amide tétrahydroquinoline
US8470852B2 (en) * 2010-08-27 2013-06-25 Gruenenthal Gmbh Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators
US8633207B2 (en) 2010-09-01 2014-01-21 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
EP2489663A1 (fr) 2011-02-16 2012-08-22 Almirall, S.A. Composés en tant qu'inhibiteurs de la syk kinase
US9051305B2 (en) 2011-03-08 2015-06-09 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
WO2012131399A1 (fr) 2011-04-01 2012-10-04 Astrazeneca Ab Traitement thérapeutique
JP2014513687A (ja) 2011-05-10 2014-06-05 メルク・シャープ・アンド・ドーム・コーポレーション Ｓｙｋ阻害薬としてのピリジルアミノピリジン
US9145391B2 (en) 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
CN103619172A (zh) 2011-05-10 2014-03-05 默沙东公司 作为syk抑制剂的氨基嘧啶
EP2736886B1 (fr) 2011-07-26 2016-09-14 Boehringer Ingelheim International GmbH Quinolines substitués et leur utilisation en tant que médicaments
WO2013052391A1 (fr) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un phényl carboxamide
EP2763976B1 (fr) 2011-10-05 2016-05-18 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 2-pyridyl carboxamide
WO2013052393A1 (fr) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 3-pyridyl carboxamide
PT2785349T (pt) 2011-11-30 2019-12-11 Astrazeneca Ab Tratamento combinado de cancro
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2013192128A1 (fr) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Analogues d'imidazolyle en tant qu'inhibiteurs de syk
US9242984B2 (en) 2012-06-20 2016-01-26 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as Syk inhibitors
US20150133450A1 (en) 2012-06-20 2015-05-14 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
US9376418B2 (en) 2012-06-22 2016-06-28 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (SYK) inhibitors
US9416111B2 (en) 2012-06-22 2016-08-16 Merck Sharp & Dohme Corp. Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors
US9353066B2 (en) 2012-08-20 2016-05-31 Merck Sharp & Dohme Corp. Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors
US9586931B2 (en) 2012-09-28 2017-03-07 Merck Sharp & Dohme Corp. Triazolyl derivatives as Syk inhibitors
US20160038503A1 (en) 2012-11-21 2016-02-11 David Richard Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
EP2757161A1 (fr) 2013-01-17 2014-07-23 Splicos miRNA-124 comme biomarqueur de l'infection virale
WO2015017788A1 (fr) 2013-08-01 2015-02-05 Eutropics Pharmaceuticals, Inc. Méthode permettant de prédire la sensibilité d'un cancer
US10640803B2 (en) 2013-10-30 2020-05-05 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
WO2015095445A1 (fr) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Composés aminohétéroaryle à substitution thiazole utilisés comme inhibiteurs de la tyrosine kinase splénique
US9783531B2 (en) 2013-12-20 2017-10-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9670196B2 (en) 2013-12-20 2017-06-06 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors
EP3116506B1 (fr) 2014-03-13 2019-04-17 Merck Sharp & Dohme Corp. Composés 2-pyrazine carboxamide utiles comme inhibiteurs de la tyrosine kinase splénique
EP2974729A1 (fr) 2014-07-17 2016-01-20 Abivax Dérivés de quinoléine utilisés dans le traitement de maladies inflammatoires
SI3212629T1 (sl) * 2014-10-31 2019-02-28 Genoscience Pharma Sas Substituiran 2,4 diamino-kinolon kot nova sredstva proti raku
CA3023032A1 (fr) * 2016-05-04 2017-11-09 Genoscience Pharma Derives substitues de 2,4-diamino-quinoleine pour leur utilisation dans le traitement de maladies proliferatives
ES2906205T3 (es) * 2017-06-14 2022-04-13 Chia Tai Tianqing Pharmaceutical Group Co Ltd Inhibidor de Syk y método de uso para el mismo
EP3658560A4 (fr) * 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. Modulateurs de la somatostatine et utilisations de ces derniers
EP3620164A1 (fr) * 2018-09-05 2020-03-11 Genoscience Pharma SAS 2,4 diamino-quinoline substituée en tant que nouveau médicament destiné à la fibrose, l'autophagie et des maladies liées aux cathepsines b (ctsb), l (ctsl) et d (ctsd)
US20220017498A1 (en) 2018-12-14 2022-01-20 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Salt of syk inhibitor and crystalline form thereof
WO2021257863A1 (fr) 2020-06-19 2021-12-23 Incyte Corporation Composés de pyrrolotriazine utilisés en tant qu'inhibiteurs de v617f de jak2
WO2021257857A1 (fr) 2020-06-19 2021-12-23 Incyte Corporation Composés naphtyridinone en tant qu'inhibiteurs de jak2 v617f
WO2022006456A1 (fr) 2020-07-02 2022-01-06 Incyte Corporation Composés de pyridone tricyclique en tant qu'inhibiteurs de v617f de jak2
CA3188639A1 (fr) 2020-07-02 2022-01-06 Incyte Corporation Composes d'uree tricycliques en tant qu'inhibiteurs de v617f de jak2
WO2022046989A1 (fr) 2020-08-27 2022-03-03 Incyte Corporation Composés d'urée tricycliques en tant qu'inhibiteurs de v617f de jak2
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
TW202302589A (zh) 2021-02-25 2023-01-16 美商英塞特公司 作為ｊａｋ２ ｖ６１７ｆ抑制劑之螺環內醯胺
WO2023099589A1 (fr) * 2021-12-01 2023-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibiteurs d'irap à utiliser pour le traitement de maladies inflammatoires

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE537104C (de) * 1926-05-04 1933-03-17 Chem Ind Basel Verfahren zur Darstellung von substituierten Chinolincarbonsaeureamiden
DE858698C (de) * 1951-02-09 1952-12-08 Basf Ag Verfahren zur Herstellung von Pyridin- und Chinolinderivaten
GB811957A (en) * 1956-03-01 1959-04-15 Geigy Ag J R Improvements relating to 2-hydroxy-4-arylamino-quinolines
WO1998018782A1 (fr) * 1996-10-28 1998-05-07 Celltech Therapeutics Limited Derives de 2-pyrimidineamine et procedes de preparation
WO2002014269A2 (fr) * 2000-08-16 2002-02-21 Neurogen Corporation Derives pyridine 2,4-substitues
WO2003078404A1 (fr) * 2002-03-15 2003-09-25 Novartis Ag Derives de pyrimidine
WO2004002960A1 (fr) * 2002-06-27 2004-01-08 Schering Aktiengesellschaft Antagonistes du recepteur ccr5 a base de quinoleine substitues
WO2004081531A2 (fr) * 2003-03-10 2004-09-23 Schering Corporation Analyse de ligands

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472066A (en) * 1949-06-07 Z-arylamino-x-halogenoqtjinolines
FR6103M (fr) * 1967-02-22 1968-06-10
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
FR2538388B1 (fr) * 1982-12-24 1985-06-21 Pharmuka Lab Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
JPH05310702A (ja) * 1992-05-06 1993-11-22 Kyowa Hakko Kogyo Co Ltd 抗炎症剤、免疫調整剤およびキノリン−２，４−ジカルボン酸ジアミド誘導体
WO1999026627A1 (fr) * 1997-11-26 1999-06-03 Cerebrus Limited (-)-mefloquine utilisee pour le blocage de recepteurs purinergiques et pour le traitement de perturbations neurodegeneratives et des mouvements
AU3386700A (en) * 1999-03-02 2000-09-21 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
EP1377554A1 (fr) * 1999-06-16 2004-01-07 University Of Iowa Research Foundation Antagonisme des oligonucleotides cpg immunostimulateurs par des 4-aminoquinolines et autres bases faibles
US6593324B2 (en) * 2000-03-01 2003-07-15 Orion Corporation Dervatives of quinoline as alpha-2 antagonists
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
KR100621287B1 (ko) * 2001-05-21 2006-09-13 에프. 호프만-라 로슈 아게 신경 펩타이드 ｙ 수용체에 대한 리간드로서의 퀴놀린유도체
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
SE0102858D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE537104C (de) * 1926-05-04 1933-03-17 Chem Ind Basel Verfahren zur Darstellung von substituierten Chinolincarbonsaeureamiden
DE858698C (de) * 1951-02-09 1952-12-08 Basf Ag Verfahren zur Herstellung von Pyridin- und Chinolinderivaten
GB811957A (en) * 1956-03-01 1959-04-15 Geigy Ag J R Improvements relating to 2-hydroxy-4-arylamino-quinolines
WO1998018782A1 (fr) * 1996-10-28 1998-05-07 Celltech Therapeutics Limited Derives de 2-pyrimidineamine et procedes de preparation
WO2002014269A2 (fr) * 2000-08-16 2002-02-21 Neurogen Corporation Derives pyridine 2,4-substitues
WO2003078404A1 (fr) * 2002-03-15 2003-09-25 Novartis Ag Derives de pyrimidine
WO2004002960A1 (fr) * 2002-06-27 2004-01-08 Schering Aktiengesellschaft Antagonistes du recepteur ccr5 a base de quinoleine substitues
WO2004081531A2 (fr) * 2003-03-10 2004-09-23 Schering Corporation Analyse de ligands

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HASEBE, M.; ET AL., TETRAHEDRON LETTERS, vol. 29, no. 48, 1988, pages 6287 - 6290, XP002445489 *
ILLUMINATI, G.; GILMAN, H., J. AM. CHEM. SOC., vol. 71, 1949, pages 3349 - 3351, XP002445491 *
SARGENT, H., J. AM. CHEM. SOC., vol. 68, 1964, pages 2688 - 2692, XP002445490 *
See also references of WO2004080463A1 *
WEISS, M.J.; HAUSER, C.R., J. AM. CHEM. SOC., vol. 71, 1949, pages 2026 - 2027, XP002445492 *

Also Published As

Publication number Publication date
EP1601357A1 (fr) 2005-12-07
CA2518398A1 (fr) 2004-09-23
MXPA05009722A (es) 2006-03-09
JP2006519846A (ja) 2006-08-31
WO2004080463A1 (fr) 2004-09-23

Similar Documents

Publication Publication Date Title
EP1601357A4 (fr) Inhibiteurs de kinase heterocycliques : procedes d'utilisation et de synthese
AU2003251559A8 (en) Heterocyclic inhibitors of kinases
IL173936A0 (en) Heterocyclic inhibitors of mek and methods of use thereof
IL181524A0 (en) Heterocyclic compounds and methods of use
PL376789A1 (pl) Pochodne aminoindazoli i ich zastosowanie jako inhibitorów kinazy
TWI346663B (en) P38 inhibitors and methods of use thereof
IL174431A0 (en) Substituted benzazoles and use thereof as inhibitors of raf kinase
PL376575A1 (pl) Podstawione związki heterocykliczne oraz sposoby wykorzystania
HK1072545A1 (en) Novel inhibitors of kinases
AU2003303128A8 (en) Inhibitors and methods of use thereof
PL378432A1 (pl) Inhibitory p38 i sposoby ich zastosowania
IL176233A0 (en) Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors
HK1160859A1 (en) Inhibitors of tyrosine kinases
IL208249A0 (en) Spirocyclic heterocyclic derivatives and methods of their use
EP1691812A4 (fr) Inhibiteurs de gtpase et procedes d'utilisation correspondants
EP1789437A4 (fr) Inhibiteurs de npc1l1 et npc1l1 et procédés d'utilisation associés
PL378116A1 (pl) Heterocykliczne inhibitory kinazy
HK1077520A1 (zh) 用作p38促細胞***原活化蛋白激酶抑制劑的吲哚類衍生物
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
EP1670422A4 (fr) Identification d'inhibiteurs de kinase
GB0511267D0 (en) Indol derivatives and their use as kinase inhibitors
ZA200500492B (en) Novel inhibitors of kinases
IL172840A (en) Benzimidazole history and their use as a protein kinase inhibitor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050913

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1077021

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20070830

17Q First examination report despatched

Effective date: 20080603

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100529

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1077021

Country of ref document: HK